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Background: Alzheimer’s disease (AD) is the most common type of dementia in the elderly. It is estimated that the
global prevalence of dementia will rise from 24.3 million in 2005 to 81.1 million in 2040. AD has a devastating
impact on sufferers, caregivers, their communities and the healthcare system in general. “Di-tan decoction” (DTD)
is a traditional Chinese medicine (TCM) formula frequently used to treat symptoms that are now defined as AD in
clinical treatment. However, the existing evidence for recommending DTD in clinical practice derives from studies
that were methodologically flawed. In this study, we aim to determine the efficacy and safety of DTD in AD
patients based on a rigidly randomized controlled trial. It will provide critical information on sample size and
treatment regimen for conducting a full-scale clinical trial of DTD later.
Methods/Design: This study will be a double-blind, randomized, placebo-controlled, add-on trial. After a 2-week
run-in period, eligible patients with mild to moderate AD will be recruited and given either DTD or placebo twice
daily for 24 weeks with follow-up 6 weeks after the last treatment. An increase of four points or greater on the
scores of Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAD-cog) will be considered as a positive
primary outcome. Total scores of the ADAD-cog, the Chinese version of Mini-Mental State Examination (C-MMSE),
and the Chinese version of the Disability Assessment for Dementia (C-DAD) score will be used as secondary
outcomes. Adverse events will also be reported.
Discussion: This randomized trial will be the first rigorous empirical study on the efficacy of DTD for treating cognitive
symptoms in AD patients. Its success will justify and warrant a large-scale clinical trial to further consolidate the
evidence for DTD’s efficacy in treating AD.
Trial registration: Chinese Clinical Trial Registry (ChiCTR-TRC-12004548, Date of registration: 22 November 2012)
Keywords: Alzheimer’s disease, Randomized controlled trial, Di-Tan decoction, Chinese medicineBackground
Alzheimer’s disease (AD) is an irreversible, progressive
neurodegenerative disorder characterized by loss of cog-
nitive functions, behavioral disturbances and daily living
difficulties [1]. It is the most common type of dementia
in the elderly [2]. Progressive atrophy is seen in all parts* Correspondence: vctmok@cuhk.edu.hk; limin@hkbu.edu.hk
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unless otherwise stated.of the brain, especially in the hippocampus region, due
to nerve cell death and tissue loss [3]. It is estimated that
the number of people suffering from dementia over the
world will rise from 24.3 million in 2005 to 81.1 million
in 2040 [4]. It is expected that a new case of AD will be
diagnosed every 33 seconds in America by 2050 [5].
AD has a devastating impact not only on sufferers, but
also on caregivers, their communities and the health
care system in general [6]. While much research is being
done on many aspects of AD, including its basic biology,
no drug has been found to alter the course of the disease
[7]. Current pharmacological treatment for AD such ashis is an Open Access article distributed under the terms of the Creative
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symptomatic and may commonly associated with some
side effects, such as nausea, vomiting, dizziness and an-
orexia [8]. Given that the efficacy is mild but with some
side effects, patients often seek alternative treatments [9].
In traditional Chinese medicine (TCM), AD is de-
scribed in terms of TCM principles; it could be caused
by (1) a deficiency of vital energy of the kidney, heart
and spleen or (2) the stagnation of blood and/or phlegm
[10]. The guidelines that classified dementia into differ-
ent subtypes according to the TCM theory was pub-
lished in 1990, and symptoms of “phlegm turbidity
obstructing the orifices” (PTOO) is considered to be one
of the major contributing factors to AD [11]. Thus, the
primary TCM strategy for treating AD is to “resolve
phlegm in order to open the orifices” [12]. The classic
Chinese medicine formula “Di-tan decoction” (DTD)
was developed by a famous TCM doctor, Dong Su, in
1449 with the specific function of “resolving phlegm to
open the orifices” [13]. It has been and still is frequently
used to treat symptoms that are now defined as AD in
clinical treatment with TCM [14,15]. In recent years,
modern studies have attempted to verify the clinical ef-
fects of DTD in biochemical terms. Laboratory studies
have shown that the memory impairment of AD model
mice was significantly reduced by DTD [16,17]. In the
brain tissue in mice treated with DTD, acetylcholine
(Ach) and acetylcholine transferase (ChAT) were signifi-
cantly increased, while acetylcholine esterase (AchE) was
decreased [18]. The results of another study indicate that
DTD may inhibit the decline of the dopamine content in
brain tissue of model mice as well [19].
In our previous systematic review, there was no clin-
ical trial using DTD as the main intervention for treating
AD. For the AD clinical trials that had involved DTD as
an adjunct intervention, we found that most of them
support the efficacy of DTD in treating AD. However,
the evidence for recommending DTD in clinical practice
derives from studies that were methodologically flawed.
None of them was a randomized controlled trial. They
not only lacked randomization, blinding, and the use of
control groups, but also failed to define inclusion and
exclusion criteria and the quality of the intervention
medicine [20]. Because of the methodological problems
in previous studies, evidence to suggest that DTD is ef-
fective in treating AD is not strong. There is a lack of
conclusive evidence to recommend a clinical trial.
As there is no basic information of DTD to conduct a
comprehensive AD clinical trial, a rigorous pilot study,
which focuses on the efficacy and safety of DTD for treat-
ing AD, will be needed before conducting a full-scale clin-
ical trial. In this study, we will evaluate the efficacy and
safety of DTD in patients with AD in a randomized con-
trolled trial. This study will be a randomized, double-blinded, placebo-controlled study, with restrictive inclu-
sion and exclusion criteria and a clearly defined quality
control intervention medicine. We hope the results from
this study will provide critical information on sample size




This study will be a double-blinded, randomized, placebo-
controlled, add-on trial. Patients with mild to moderate
AD will be randomly assigned to receive 24 weeks of ei-
ther active herbal treatment or placebo (in a 1:1 ratio);
they will be followed for a further 6 weeks’ observation
period without treatment. This clinical study will be car-
ried out at the Hong Kong Baptist University Chinese
Medicine Specialty Centre. It has been approved by the
Ethics Committee of the Hong Kong Baptist University’s
Institutional Review Board (code: HASC/11-12/24) and
registered with the Chinese Clinical Trial Registry
(ChiCTR-TRC-12004548). If there is any amendment to
the protocol, approval must be again sought from the
Ethics Committee. Written informed consent will be
obtained from every patient before participation in any
study-related activity. The protocol design is based on
the guidelines of Consolidated Standards of Reporting
Trials (CONSORT) and Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) [see
Additional file 1], and study results will be reported ac-
cording to these guidelines as well.
Participants
Inclusion criteria are as follows: Adults who (1) have
been clinically diagnosed with AD based on the criteria
of National Institute of Neurological and Communica-
tive Disorders and Stroke and Alzheimer’s Disease and
Related Disorders Association (NINCDS/ADARA) [21],
and (2) present symptoms classified as PTOO [see
Additional file 2] as defined by the Guidance for Clinical
Research of New Chinese Herbal Medicine [22] during a
screening visit, will be eligible. The diagnostic criteria of
PTOO include dementia, heavy-headedness and spitting
phlegm. Additional inclusion criteria are as follows:
(1) mild to moderate dementia with ≥2 on Clinical Demen-
tia Rating Scale (CDR) [23]; (2) receiving a stable dose of
anti-dementia medication (that is, Donepezil, Rivastigmine
and Memantine) for at least 4 weeks before the start of
treatment; and (3) normal liver and renal function.
Exclusion criteria are as follows: Patients who also
have any other type of dementia (that is, vascular de-
mentia), and/or other neurodegenerative disorder (that
is, Parkinson’s disease), depression (defined by a score
of ≥8 on the 15-item Chinese version of the Geriatric
Depression Scale [24]), or who are unwilling to cooperate
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who have participated in other trials within 30 days of the
start of this trial as well as women who are pregnant or
breastfeeding will also be excluded.
Study medication
The herbal medicine under study is DTD (Table 1). It
is composed of Arisaema Cum Bile (DanNanXing in
Chinese), Pinelliae Rhizoma (FaBanXia in Chinese),
Aurantii Immaturus Fructus (ZhiShi in Chinese), Poria
(FuLing in Chinese), Citri Reticulatae Pericarpium
(ChenPi in Chinese), Acori Tatarinowii Rhizoma
(ShiChangPu in Chinese), Ginseng Radix (RenShen in
Chinese), Bambusae in Taeniam Caulis (ZhuRu in
Chinese), Glycyrrhizae Radix (GanCao in Chinese),
Zingiberis Recens Rhizoma (ShengJiang in Chinese)
and dextin [13]. The test report of the DTD quality
control is attached in the Additional file 3. The placebo
is made of caramel (2%), gardenia yellow pigment
(0.05%), sunset yellow (0.02%), tartrazine (0.02%), dex-
trin (95%) and broadleaf holly leaf (2.91%) [25]. The
granules were produced in a single batch (DTD batch
no.: A12074 Placebo batch no.: A120817) strictly in com-
pliance with standards of Good Manufactory Practice
(GMP) and Chinese Pharmacopoeia 2010 to ensure the
stability and homogeneity of the composition as produced
by PuraPharm Pharmaceuticals Company Limited. The
chemical compositions of the final products were analyzed
for contamination with heavy metals, toxic elements, mi-
crobe and pesticide residues; both final products were ana-
lyzed for stability and adherence to quality standards. The
active treatment granules and the placebo granules have
identical appearance and smell, and both have been
packed in sealed opaque aluminum sachets and put in zip
lock bags (10 sachets each). Only the treatment code is
printed on the package to ensure successful blinding of
patients [26]. One sachet contains 13.5 g, a dosage equiva-
lent to 67.5 g herbs. All herbal and placebo granules willTable 1 “Di-tan decoction” (DTD) composition
Chinese name Latin name Percentage
Dan Nan Xing Arisaema Cum Bile 11.42
Ban Xia Pinelliae Rhizoma 11.42
Zhi Shi Aurantii Immaturus Fructus 9.13
Fu Ling Poria 9.13
Chen Pi Citri Reticulatae Pericarpium 6.84
Shi Chang Pu Acori Tatarinowii Rhizoma 4.55
Ren Shen Ginseng Radix 4.55
Zhu Ru Bambusae in Taeniam Caulis 3.19
Gan Cao Glycyrrhizae Radix 2.29
Sheng Jiang Zingiberis Recens Rhizoma 18.10
Dextrin - 19.36be distributed by L.L. Chen with both written and verbal
instructions for each participant. Patients will be
instructed to take the granules orally by dissolving a sachet
of granules in 150 ml hot water, stirring well, then drink-
ing the solution, two times per day, at least two hours
apart from taking any routine Western medication. Pa-
tients will be allowed to discontinue the study granules
temporarily if any adverse events occur. Patients will be
instructed to report such events to a special e-mail ac-
count or by a direct telephone line. Additional treatments
for a newly occurring illness, for example, flu or diarrhea,
or adverse event during the study will be allowed but must
be reported to the assessor.
Recruitment procedures
Three methods will be used to recruit participants with
AD. The first source of candidates will be referral from
two public Western medicine hospitals in Hong Kong
(Prince of Wales Hospital and Queen Elizabeth Hospital)
from our co-investigator (Co-I), V. Mok, and our research
teammate, A.L.T. Chan. The second source will be referral
from the Chinese medicine clinic of Hong Kong Baptist
University. A third source of candidates will be those who
respond to advertisements published in local newspapers
and newsletters of local AD societies.
Figure 1 shows the schedule of enrollment. We plan to
recruit at least 40 patients, which will allow 20 for the
DTD group and 20 for the placebo group in this study. All
patients diagnosed with AD will be referred to a Chinese
medicine doctor who is the Principle Investigator of the
study (M. Li), or to a Research Assistant (K.K. Chua), for
further assessment and recruitment. The aim, procedures,
nature of study and possible side effects of DTD will be
explained by the PI or RA; then, each subject will be asked
to sign a written consent [see Additional file 4] to take
part in the study. Patients will be informed that they are
free to withdraw at any time during the study.
All patients will undergo a 2-week run-in period, in
which they have to keep their Western medicine and
supplement dosages fixed. Their blood will be tested to
check liver function (alanine transaminase (ALT)/serum
glutamic pyruvic transaminase (SGPT), aspartate trans-
aminase (AST)/ serum glutamic oxaloacetic transaminase
(SGOT), alkaline phosphatase, gamma glutamyltransfer-
ase, total bilirubin, total protein, albumin) and renal func-
tion (urea, creatinine, sodium, potassium, chloride,
bicarbonate) in a lab test center designated for the project.
Randomization and masking
The randomization sequence will be generated by SPSS
19.0 package (SPSS, Chicago, IL). The sequence will be
password-protected and kept in a computer by L.L.
Chen. Group allocation will be simple randomization in
a ratio of 1:1 to either active treatment group or placebo
 Randomization &  
2 weeks Run-in period 
Patients fulfill the inclusion 
and do not fulfill exclusion 
criteria
Patients do not fulfill the 
inclusion or fulfill the exclusion 
criteria
Agree to participate Disagree to participate 
Exclusion 
DTD group Placebo group 
Screening
  24 weeks  
Treatment period 
  6 weeks  
Observation period 
AD Patients
Figure 1 Schedule of enrollment.
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opaque envelopes and distributed to assessors. Patients,
investigators and all sponsoring parties will be masked
to treatment allocation until the end of the study. When
there is a serious adverse event, the event will be dis-
cussed between the principal investigator Chinese medi-
cine expert M. Li, and the co-investigator neurology
specialist V. Mok to consider unblinding.
Primary outcome and its assessment
A positive primary outcome of this study will be an in-
crease of at least four points in the Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAD-cog) [27]
total score; this is considered to be a clinically meaning-
ful increase [28]. Total scores of the ADAD-cog, Chinese
version of Mini-Mental State Examination (C-MMSE)
[29,30] and Chinese version of Disability assessment for
dementia (C-DAD) score [31] will be used as secondary
outcomes.
Outcome measurements will be carried out during the
study visits at weeks 0, 12 (half of treatment), 24 (end of
treatment) and 30 (end of observation period). Safety as-
sessment, which includes reporting of adverse events
(AEs), measurement of vital signs and physical examin-
ation, will be carried out throughout the study. In
addition, laboratory safety screening of liver and renalfunction will be performed at week 24. Bilingual asses-
sors, trained by the same neurology specialist V. Mok
and clinical psychologist A. Wong, will be blind to the
treatment allocation.
Clinical assessment will be rescheduled within 7 days
after the scheduled clinical visit in case of any unex-
pected condition such as severe weather conditions.
Phone call reminders will be given to the caregivers one
day before the days of assessment.
A home diary will be given to each study participant’s
caregiver to record treatment and changes in the partici-
pant’s medical condition. Formal instruction for the
home diary will be given during the first visit. Revision
and checking of the diary will be carried out with the
caregiver during each formal visit by the assessors. Com-
pliance in taking the treatments will be determined by
the record of the diary and the number of the returned
medicine/placebo packages.
Data management and monitoring
All the data will be entered and stored in a password-
protected computer. Hardcopy will be kept in a locker.
No interim analyses will be carried out. To ensure high
quality of the data, a double data entry method will be
used. All documents and collected data will be kept for
7 years after the finish of study and then will be
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published in a scientific journal where the public will
have access to all the results.
A data monitoring committee (DMC) will be formed
and will include at least two faculty members from the
participating universities, who are independent of the re-
search team and who will not participate in any other
aspect of the study. The data management process will
be monitored by DMC regularly. All the data will be fro-
zen and then locked to prevent further editing after the
validation by the DMC. Only the DMC, the study re-
search assistant and the principal investigator will have
access to the final dataset.
Statistical analysis
The proportion of patients with at least a four-point
change in ADAS-cog and MMSE and the scores on C-
DAD will be compared between the active treatment
and placebo groups using the Chi-Squared test and in-
dependent sample t test, respectively. Missing data will
be input using the last-observation-carried-forward
(LOFC) approach. All patients randomized with at least
one post-randomization measurement will be included
in the primary analysis to follow the intention-to-treat
principle. Analyses will be done with SPSS 19.0 package
(SPSS, Chicago, IL).
To get a more comprehensive picture of the efficacy of
DTD, a post-hoc analysis of the differences in the
change of ADAS-cog and C-DAD sub-scores of the ac-
tive treatment group will be compared between the ac-
tive and placebo groups. To reduce the number of
statistical comparisons, analyses will be performed with a
hierarchical approach. To begin, the scores of ADAS-cog
at week 24 (end of treatment) for the active treatment and
placebo groups will be compared. If the difference is
deemed statistically significant at a 2-sided α-level of 0.05,
the scores of ADAS-cog at week 12 (half of treatment)
and week 30 (end of observation period, that is, without
treatment) will be compared between groups. C-DAD will
be analyzed in the same manner as ADAS-cog.
Compliance strategy
This will be a 30-week clinical trial, in which subjects
will need to take study medication for 24 weeks with 8
regular visits (week 0, 4, 8, 12, 16, 20, 24 and 30). In
order to maximize subjects’ compliance, first, we will
have a thorough consent process for all participants; we
will explain in detail the study schedule, potential side
effects of treatment, and the responsibilities of the sub-
jects. Second, we will screen potential subjects carefully
during a 2-week run-in period in order to exclude ineli-
gible patients or patients who are unlikely to comply
with treatment regimen before randomization. Third, we
will try to prevent dropouts by providing ongoingsupport to patients. A special e-mail account and a dir-
ect telephone line set up for this clinical trial will enable
the study team to personally communicate with the pa-
tients. An information sheet will be given to each par-
ticipant providing them and their caregivers with means
of urgent contact. Extra visits and free medical care will
be arranged for any participant who feels harmed by the
trial protocol. Fourth, this is an add-on design [32],
which means that the study treatment is added to their
existing treatment. Certainly those participants receiving
the placebo should not experience any difference in their
condition, while those receiving the DTD should im-
prove or at least remain the same.
Early termination
The trial will be terminated for a specific participant in
the event of any of the following: (1) participant develops
severe adverse side effect(s); (2) participant shows hyper-
sensitivity towards DTD; (3) participant develops some
other life-threatening condition or disease; or (4) partici-
pant chooses to participate in another Chinese medicine
research project. In addition, any participant may volun-
tarily withdraw.
The whole research plan will be terminated under the fol-
lowing circumstances: (1) presence of serious adverse ef-
fect(s) related to Chinese herbal medicine with supportive
evidence or (2) completion of all follow-up assessments.
Discussion
AD, as a progressive neurodegenerative disorder, has dev-
astating impacts not only on patients but also on family
members, friends, and caregivers. A cure would bring im-
measurable relief and hope to countless thousands. Unfor-
tunately, western pharmacological research has been
unsuccessful in finding effective treatment without serious
side effects [8]. In this case, Chinese medicine may have
something to offer. Chinese medicine has been used to
treat neurological diseases for thousands years with effi-
cacy, safety, and relatively few side effects - albeit without
rigorous and objective testing [33].
This randomized trial will be the first rigorous testing
of DTD for the treatment of AD patients. Success in this
clinical trial will provide evidence acceptable to the sci-
entific community of the potential of DTD to become
an effective medicine for AD. The success of this study
would represent justification and impetus for a large-
scale clinical trial to further consolidate the evidence for
the use of DTD in the treatment of AD.
It is noted that the sample size calculation does not
apply to this study. Normally, 10 to 20 patients in each
group would be sufficient to implement the method of a
pilot study [34]. Since there is no previous data indicat-
ing the sample size needed to unequivocally determine
the effect of DTD by the ADAS-cog, the evidence will
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less, the one aspect of this study that could undermine
its value is sample size. There is no information on what
sample size is needed to give statistically significant re-
sults. On the other hand, this study could find out what
specific symptoms, like mood or cognitive, that DTD
may improve. This information should be an important
evidence for a much precise clinical trial with larger
sample size in the future.
In conclusion, the results of this study are expected to
provide evidence for the efficacy and safety of the Chinese
herbal formula, DTD, for treatment of AD patients who
also meet the diagnostic criteria of “phlegm obstructing
the orifices” syndrome according to TCM diagnostics. It
may also provide a new direction for the clinical research
on AD and TCM.
Trial status
The trial has been approved and registered. At the time
of manuscript submission, the study has been actively
enrolling subjects, and so far has a total of 36 subjects.
The study is still ongoing. Herbal and placement packets
have been produced.
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